<DOC>
	<DOCNO>NCT02370498</DOCNO>
	<brief_summary>This study participant advance gastric gastroesophageal junction adenocarcinoma tumor progression first-line treatment platinum fluoropyrimidine doublet therapy . The primary study hypothesis pembrolizumab prolongs progression free survival ( PFS ) overall survival ( OS ) participants tumor show positive program cell death ligand 1 ( PD-L1 ) expression .</brief_summary>
	<brief_title>A Study Pembrolizumab ( MK-3475 ) Versus Paclitaxel Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum Fluoropyrimidine ( MK-3475-061/KEYNOTE-061 )</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Have histologically cytologicallyconfirmed diagnosis gastric gastroesophageal junction adenocarcinoma Confirmed metastatic locally advanced , unresectable disease ( CT scan clinical evidence ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Progression prior firstline therapy contain platinum/fluoropyrimidine doublet Willing provide tumor tissue PDL1 biomarker analysis ( new archive specimens agreement Sponsor ) HER2/neu status know participant HER2/neu positive tumor show documentation disease progression treatment contain trastuzumab Female participant childbearing potential willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose pembrolizumab 180 day last dose paclitaxel . Male participant agree use adequate method contraception start first dose study therapy 120 day last dose pembrolizumab 180 day last dose paclitaxel . Adequate organ function Currently participate receive study therapy , participate study investigational agent receive study therapy use investigation device within 4 week first dose medication Squamous cell undifferentiated gastric cancer Active autoimmune disease required systemic treatment past 2 year ( replacement therapy consider form systemic treatment Diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study medication Prior anticancer monoclonal antibody ( mAb ) within 4 week prior study Day 1 recover adverse event due agent administer 4 week earlier Prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 recover adverse event due previously administer agent surgery Known additional malignancy progress require active treatment ( exception basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy ) Known active central nervous system ( CNS ) metastases and/or carcinomatous meningitis History evidence interstitial lung disease active noninfectious pneumonitis Active infection require systemic therapy Known psychiatric substance abuse disorder would interfere cooperation requirement trial Pregnant breastfeeding , expect conceive father child within project duration trial , start screen visit 120 day last dose pembrolizumab 180 day last dose paclitaxel . Prior immunotherapy include antiPD1 , antiPDL1 , antiPDL2 agent , previously participate Merck pembrolizumab ( MK3475 ) clinical trial Known history human immunodeficiency virus ( HIV ) Known active Hepatitis B Hepatitis C Live vaccine within 30 day plan start study therapy Known allergy hypersensitivity paclitaxel component use paclitaxel preparation contraindication taxane therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Gastric cancer</keyword>
	<keyword>Gastroesophageal junction cancer</keyword>
</DOC>